CCL2 and cancer: As for mode of action, it appears plausible that NAM acts as a therapeutic agent by re-establishing T cell-dependent immunosurveillance via both direct (T cell activation) and indirect (type I IFN and CCL2 secretion by cancer cells) mechanisms.